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Abstract
Objectives To assess the use of MRI-determined tumour re-
gression grading (TRG) in local response assessment and de-
tection of salvageable early local relapse after chemoradio-
therapy (CRT) in patients with anal squamous cell carcinoma
(ASCC).
Methods From a prospective database of patients with ASCC
managed through a centralised multidisciplinary team, 74 pa-
tients who completed routine post-CRT 3- and 6-month MRIs
(2009–2012) were reviewed. Two radiologists blinded to the
outcomes consensus read and retrospectively assigned TRG
scores [1 (complete response) to 5 (no response)] and related
these to early local relapse (within 12 months) and disease-
free survival (DFS).
Results Seven patients had early local relapse. TRG 1/2 scores
at 3 and 6months had a 100% negative predictive value; TRG
4/5 scores at 6 months had a 100 % positive predictive value.
All seven patients underwent salvage R0 resections. We iden-
tified a novel ‘tram-track’ sign onMRI in over half of patients,
with an NPV for early local relapse of 83 % at 6 months. No
imaging characteristic or TRG score independently prognos-
ticated for late relapse or 3-year DFS.
Conclusions Post-CRT 3- and 6-month MRI-determined
TRG scores predicted salvageable R0 early local relapses
in patients with ASCC, challenging current clinical
guidelines.
Key Points
• Post-chemoradiotherapy MRI (3 and 6 months) helps local
response assessment in ASCC.
• The MRI-TRG system can be used reproducibly in patients
with ASCC.
• The TRG system facilitates patient selection for examination
under anaesthesia and biopsy.
• The use of MRI-TRG predicts for detection of salvageable
early local relapses.
• The TRG system allows for a standardised follow-up
pathway.
Keywords Magnetic resonance imaging . Anus neoplasms .
Carcinoma, squamous cell . Chemoradiotherapy . Tumour
response
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Introduction
For patients with anal squamous cell carcinoma (ASCC), trials
performed in the 1990s [1, 2] established chemoradiotherapy
(CRT) as standard initial treatment. Despite these improve-
ments, recent trials [3, 4] continue to observe early local re-
lapse, within the first 12 months, of approximately 10 % after
CRT [4], and total local relapse rates (additionally including
late local relapses after an initial disease-free period) between
18 % and 25 % [3, 5]. Salvage radical surgery, typically in the
form of abdomino-perineal resection, offers a second chance
for cure in these patients with R0 resection (microscopic neg-
ative margins) [6]. However, many institutional series report
post-salvage resection positive margin (R1/R2) rates between
16 % and 20 % [7–10], and as high as 32 % in population
registries [11]. For patients with R1/R2 resections, post-
salvage survival rates are dismal – typically zero survival at
3–5 years [5, 7, 10, 11] – rates equivalent to those observed in
patients with local relapse not undergoing salvage surgery [5],
thus questioning patient benefit from such radical surgery.
Against the above background, follow-up should be directed
towards the early detection of salvageable local relapse. Here,
we posit (contrary to current guidelines, below) that magnetic
resonance imaging (MRI), the imaging modality of choice for
locoregional staging [12–15], has a role in post-CRT assess-
ment of treatment response and detection of salvageable local
relapse, and specifically test this hypothesis for early local
relapse in the first 12 months (when 60 % of all local relapses
occur [5]).
Guidelines from the European Society for Medical
Oncology (ESMO) recommend clinical evaluation for com-
plete response at 8 weeks post-CRT and then 3- to 6-monthly
thereafter for a 2-year period, stating that BMRI can capture and
document response, but no individual MRI feature appears pre-
dictive of eventual outcome^ [14]. The ESMO guidelines en-
dorse a ‘watchful wait’ approach, stating that Bpartial regression
can be managed by close follow-up, to confirm that (a delayed)
complete regression takes place, which may take 6 months^.
The US National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines make no specific reference to the
role of MRI in post-CRT surveillance [16], and the American
Society of Colon and Rectal Surgeons guidance [17] does not
endorse a role for MRI post-CRT surveillance, citing evidence
that MRI is not a predictor of clinical response in early (6–8
weeks) follow-up of CRT [13] and that longer term (6–12
months) MRI evaluation can demonstrate changes in tumour
size and a reduction/stabilisation of signal intensity, but corre-
lates only modestly with outcome [13]. However, both cited
series supporting this recommendation were limited to small
sample sizes (35 [13] and 15 [18] patients, respectively) and
optimal timing of MRI post-CRT remains unclear [19].
At our centralised anal cancer multi-disciplinary team
(MDT) we have long had a proactive (rather than a watchful
wait) approach to the detection and surgical intervention for
early local failure after CRT in patients with ASCC [5, 6].
Since 2009, this protocol has included routine post-treatment
MRI assessment at 3 and 6 months. The primary aim of this
study was to determine the use of this MRI-inclusive protocol
to assess tumour response and the detection of salvageable
early local failure after CRT. To this end, we extended the
use of the MRI tumour regression grading (TRG) system used
in other tumour settings (such as oesophageal [20] and rectal
cancer [21, 22]) and established good reproducibility. As a
secondary aim, we identified and described a novel ‘tram-
track sign’ as a putative indicator of complete local tumour
response, and evaluated its significance.
Materials and methods
Patients and treatment
Between 2009 and 2012, 118 patients were managed consec-
utively through our centralised MDT for patients with anal
malignancies. To investigate the relationship between MRI
changes from baseline to 3 and 6 months post-CRTwith early
outcomes, patients who satisfied the following criteria were
included: (1) histological confirmation of ASCC without met-
astatic disease at baseline; (2) the presence of a demonstrable
anal lesion on baseline staging MRI; (3) standard treatment
with CRT including an inguinal radiation boost where indicat-
ed; (4) follow-up MRI scans at 3 and 6 months post-CRT
(±2 weeks on either side); (5) histological correlation with
examination under anaesthesia (EUA) and biopsy or at least
2 years’ follow-up post-CRT. This approach mimicked a per-
protocol analysis of routine 3- and 6-month MRI surveillance.
Seventy-four patients met these criteria.
The following patients were excluded: no demonstrable
lesion on stagingMRI, 15; inadequate follow-up, 15 (6-month
post-treatment MRI not done in 12 and delayed timing of
post-treatment scans in three); recurrent ASCC, four; ectopic
or multifocal SCC, five; other histological subtypes, five. This
retrospective study was approved by the institutional audit and
service improvement committee and informed consent was
waived.
All patients received CRT using the UK National Anal
Cancer Trial (ACT II) protocol [4]. Radiotherapy of 50.4 Gy
was delivered in 28 daily fractions (F) over 5.5 weeks with a
two-phase technique. Phase 1 delivered 30.6 Gy (17 F) using
non-conformal rectangular parallel-opposed fields aiming to
treat all pelvic nodes (except the common iliac); phase 2 was
conformally planned using CT images to deliver 19.8 Gy
(11 F) over 15 days treating the primary tumour and the whole
anal canal with a 3-cm margin around the macroscopic tu-
mour. Patients received fluorouracil 1,000 mg/m2 per day on
days 1–4 (week 1) and 29–32 (week 5) by continuous 24-h
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intravenous infusion with radiotherapy and 12 mg/m2 of mi-
tomycin as an intravenous bolus on day 1 only.
Magnetic resonance imaging (MRI) and staging
All baseline staging MRI scans were performed on a 1.5-T
MRI unit employing a pelvic phased-array body coil. The
acquisition protocol is detailed in Table 1 (Supplementary
file). The same protocol was performed for post-CRT MRI.
Multiparametric imaging with dynamic post-contrast se-
quences (DCE) and diffusion-weighted imaging (DWI) are
not routinely used in our clinical practice as these are still
considered research modalities [23]. The baseline and post-
CRT MRI scans were reviewed, blinded to outcome, by two
radiologists with 25 and 8 years’ experience, respectively, in
reading pelvicMRI, assigning final TRG scores by consensus.
The following primary tumour features were assessed: size
(the maximum diameter in any plane measured on the high
resolution T2W image to the nearest millimetre); position
(anal canal, anal margin); circumferential tumour extent (po-
sition on clock); subjective T2W signal intensity (high–similar
to fluid; low–similar to muscle and intermediate); infiltration
of adjacent organs (vagina, prostate); trans-sphincteric exten-
sion into the ischioanal/ ischiorectal fossa; and the presence of
perianal fistulas or abscesses. Regional and metastatic lymph
node involvement was reported using accepted size criteria
[24] and signal intensity characteristics. Nodal sites were de-
fined and tumour stage was recorded using the AJCC TNM
system, seventh Edition [25].
MRI and treatment response evaluation
Tumour response was evaluated on the 3- and 6-month post-
treatment MRI scans. Residual tumour size was recorded and
if there was no suspicious residual focus, then the tumour was
considered to have completely responded. Regression or en-
largement of malignant nodes seen on staging MRI or any
new suspicious lymph node enlargement was also recorded.
Development of metastatic disease on follow-up was
recorded. We also correlated primary tumour stage with local
tumour response.
Tumours response was additionally scored 1–5, using the
Mandard tumour regression grading (TRG) system (Table 1),
similar to that used after CRT for rectal cancer [21, 22]. TRG
scores were given based on careful analysis of the signal in-
tensity changes on the post-CRT MRI scans and correlation
with baseline MRI to match with the original tumour location
and characteristics.
In patients with tumours involving the anal canal, the pres-
ence of a novel ‘tram track’ signwas recorded on the post CRT
MRI scans. This was defined as parallel linear low signal at
the inner and outer margin of the internal sphincter, at the site
of the original tumour (Fig. 1a–c). This sign was analysed as a
marker of complete local tumour response.
Follow-up and outcomes
Clinical assessment was first performed in all patients at
6 weeks after completion of CRT and again at clinical visits
paralleling the 3- and 6-month scans. Based on the findings of
clinical assessment supplemented with the MRI findings, pa-
tients were subjected to EUAwith or without biopsy to con-
firm or exclude local disease relapse.
Statistical analysis
All computations were performed using Stata™ 12.0 (College
Station, TX, USA). TRG scores were correlated with the sub-
sequent development of early local relapse (defined as within
12 months following CRT completion) to estimate perfor-
mance characteristics (sensitivity, specificity, positive predic-
tive value (PPV) and negative predictive value (NPV)) by
categorising TRG scores as follows: patients with TRG grades
1 or 2 were grouped together as complete responders and
those with grades 4 or 5 as non-responders. TRG grade 3
was the indeterminate group.
We determined actuarial rates for local relapse and disease-
free survival (DFS) using standard Kaplan-Meier curves.
Events in the DFS analyses were: any local relapse, distant
Table 1 Tumour regression




Grade 1 Complete response with no evidence of tumour and normal appearances of the anus
Grade 2 Excellent response with only low signal post treatment fibrotic
change and no evidence of tumour
Grade 3 Moderate response with indeterminate heterogeneous signal intensity at the tumour site
Grade 4 Minimal response with reduction in size but evidence of intermediate
tumour signal in keeping with residual disease
Grade 5 No response of the primary tumour or frank tumour progression
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metastases and death from any cause. Actuarial rates for local
relapse were from date of completion of CRT; those for DFS
were from start date of initial treatment.We tested a number of
patient, tumour and imaging characteristics against DFS and
estimated effects sizes (expressed as hazard ratios (HRs) and
their 95 % confidence intervals (CIs)) using Cox models. We
derived the final models using a seven-step approach as we
have previously described [26], exploring for confounding
interactions, collinearity problems, predictive accuracy and
calibration.
Reproducibility (inter-reader agreement) was assessed by
calculating the k (kappa) values, including a weighting option
to weight for clinically important disagreements, and
interpreted as follows: less than 0.20, poor agreement; 0.21–
0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–




All 74 patients had histologically confirmed anal SCC. Of
these, ten were well differentiated, 25 were moderately
Fig. 1 Demonstrative figure showing the normal anal anatomy in row ‘a’
(line diagram representation in left column, high resolution T2W MR in
the coronal plane in mid column and in the axial plane in the right hand
column). Row ‘b’ demonstrates an upper anal canal tumour involving the
left internal sphincter extending from the 2 o’clock to 6 o’clock position
(arrows). Post-CRTappearances in row ‘c’ showing the tram track sign as
parallel bands of low signal along the inner and outer margins of the left
internal sphincter at the site of original tumour (arrows)
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differentiated and 14 were poorly differentiated SCCs, and in
25 patients this information was not available.
Baseline characteristics
The baseline characteristics of the 74 patients with histologi-
cally confirmed ASCC are listed in Table 2. In common with
most treatment series from European populations [28], fe-
males accounted for approximately 55 % of patients. There
were five patients with confirmed HIV positivity. Only five
tumours (7 %) were fully confined to the anal margin, the
remainder arising solely in the anal canal or overlapping the
anal canal and margin. Approximately two-thirds of these
were stage T2, approximately half were node positive.
Follow-up and local relapse
As per inclusion criteria for analysis, all patients had a mini-
mum of two post-treatment MRI scans. Clinical follow-up of
over 2 years after CRTwas available in 67 of the 74 patients.
Of the seven patients who did not have a follow-up of over
2 years, six had died in the interim (four from unrelated causes
and two due to metastatic disease from anal cancer) and one
patient did not attend any further follow-up. During the first
12 months, EUA and biopsy was performed in 32 of the 74
patients.
With a median follow-up of 52 (range 9–72) months after
completion of CRT, there were 11 (15 %) local relapses; seven
(9 %) were early relapses (within the first 12 months) and four
were late relapses (in this series, all late local relapses were
after 24 months) (Fig. 2). The 3-year actuarial rate of local
relapse was 14 % (95 % CI: 8–24). Among the seven patients
with early local relapse, there was a relationship with increas-
ing T-stage as follows: T1: 0/4; T2: 4/50 (8 %); T3: 1/10
(10 %); and T4: 2/10 (20 %).
Post-treatment MRI findings
Following treatment, there was a reduction in tumour size at
3 months (mean reduction 28.79 %, range 0–100) and
6 months (mean reduction 81.39 %, range 0–100). There
was a subjective reduction in signal intensity of the primary
tumour compared to baseline in 69 % (51/74) of patients on
the 3-month scan and in 84 % (62/74) of patients on the 6-
month scan. Nodal disease was down staged in 33 of the 36
patients, with N0 status in 32 of these patients.
Tumour regression grading (TRG) score
The TRG scores on the post-treatmentMRI at 3 and 6 months,
temporal score change and correlation with local relapse are
Table 2 Baseline characteristics in 74 patients with anal squamous cell
carcinoma (ASCC)
Characteristic
Median age (range) year 60 (33 to 86)
Male : female 34 : 40




Both canal and margin 11 (15)
Circumferential involvement
Entire anal circumference 18 (24)
Greater than 50 % circumferential 17 (23)
Less than 50 % circumferential 39 (53)
Tumour extension into lower rectum 32 (50)
Transphincteric extension 13 (18)











Note: Values in parentheses are percentages unless otherwise stated
*Vagina, 8; prostate, 2
Other features: perianal fistula, 4; abscess, 1
Fig. 2 Time to event plot for local relapses after chemoradiotherapy
(CRT) shown by early (within 12 months) and late (after 12 months)
relapses. Short vertical hashes represent censored events. Markers in
upper panel indicate local relapse events: blue, early relapses; orange,
late relapses
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summarised in Fig. 3. All seven patients underwent salvage
R0 resections. High-resolution images and case studies of the
TRG scoring for anal cancers are shown in Figs. 4 and 5
(Figs. 1 and 2 are Supplementary files). Performance charac-
teristics by various TRG models for 3- and 6-month TRG
scores and changes with time are shown in Table 2
(Supplementary file). All patients who demonstrated TRG 1
and 2 on 3- and 6-month post-CRT MRI scans showed no
evidence of early local relapse. This gave a negative predictive
value of 100 % for early local relapse. On the 6-month MRI,
all four patients with TRG 4 and 5 had histological confirma-
tion of residual disease on EUA. This gave a positive predic-
tive value of 100 % for residual disease. Table 2
(Supplementary file) also shows four patterns of TRG changes
between 3- and 6-month scans: TRG1/2 stable (35 %); TRG3,
further regression (38 %); TRG3 stable (22 %); and progres-
sion (5 % or four cases). However, this categorisation did not
appear to add additional discrimination above and beyond
those models for TRG scored at 3 and 6 months and simply
compared with baseline scans.
Tram-track sign
We identified a novel post-treatment ‘tram-track’ sign on
MRI. This was a parallel linear low signal at the inner and
outer margin of the internal sphincter, at the site of the original
tumour. This is due to a band-like fibrotic treatment response
in the muscularis sub-mucosa and bands of fibrosis in and
between the smooth muscle of the internal sphincter, and the
skeletal muscle of the external sphincter which is relatively
spared (histology of the same patient as in Fig. 1 is shown in
Supplementary Fig. 1d).
We tested the hypothesis that this sign is a marker of com-
plete local tumour response. Of the 69 patients with anal canal
tumours, the tram-track sign was seen in 48 % (33/69) on the
3-month scan, and in 57 % (39/69) on the 6-month MRI scan.
Of these 39 patients, only one developed early local disease
relapse. At presentation this patient had a large tumour involv-
ing both the canal and the margin, and early relapsed disease
occurred in the anal margin separate from the tram-track sign



















3 of 19 had 
local disease 
relapse




















Fig. 3 Tumour regression
grading (TRG) scores on post-
treatment magnetic resonance
imaging (MRI) correlated with
local disease relapse. SCC
squamous cell carcinoma
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Disease-free survival
During follow-up, in addition to local relapses, metastatic dis-
ease was detected in seven patients. For all patients, the 1-year
and 3-year DFS rates were 85 % (95 % CI: 75–92) and 72 %
(95 % CI: 60–80). We tested various patient, tumour and im-
aging characteristics against DFS (Table 3, Supplementary
file). By univariate analyses, the following factors were sig-
nificant: performance status; T-stage; circumferential involve-
ment, trans-sphincteric extension, involvement of adjacent
Fig. 4 High resolution coronal T2-weighted images (a, b, d). Baseline
magnetic resonance image (MRI) (a), showing an intermediate signal
intensity tumour (arrow) in the lower anal canal extending to the verge.
The 3-month post-chemoradiotherapy (CRT) MRI (b) shows response to
treatment but with mixed low and high signal areas at site of original
tumour (arrow), this was considerate indeterminate for residual disease
versus inflammation, tumour regression grading (TRG) score 3.
Photomicrograph with H & E stain and 20X magnification (c), showing
partially organising and inflamed granulation tissue with no viable resid-
ual tumour, this correlates with TRG 3 on the post-CRT MRI. The 6-
month post CRT MRI (d) now shows improvement in appearances with
low signal change and no evidence of any suspicious intermediate signal
indicating the previously noted changes due to inflammation had re-
solved, downgrading the TRG score to 2
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organs, TRG 4/5 at 3 months and 6 months. By multivariate
modelling, testing for independence, only the following
remained significant: performance status and T-stage (border-
line). No imaging characteristic or TRG score inde-
pendently prognosticated for late relapse or 3-year
DFS.
Reproducibility of the tumour regression grading
The inter-rater kappa values for the TRG scores on the 3- and 6-
month scans were 0.61 and 0.76, respectively, demonstrating
good inter-rater agreement in accordance with the priori criteria
[27].
Fig. 5 High resolution axial T2-weighted images (a-c). Baseline
magnetic resonance image (MRI) (a), showing an intermediate signal
intensity tumour (arrows) in the anal canal extending from the 5 o’clock
to 11 o’clock position. The 3-month post-chemoradiotherapy (CRT)MRI
(b), shows decrease in size but residual intermediate signal remains of
concern for tumour (arrow), tumour regression grading (TRG) score 4.
The 6-month post CRT MRI (c) shows interval progression with central
cavitation of the suspected residual tumour (arrow), TRG score 5.
Photomicrograph with H & E stain and 4X magnification showing
residual viable invasive squamous cell carcinoma (star shape)
associated with some underlying stromal hyalinisation (triangle shape)
in response to prior radiotherapy, these histological features correlate
with Grades 4 to 5 on the post-CRT MRI. The patient subsequently
underwent radical surgery with flap reconstruction
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Discussion
The role and timing ofMRI for post-CRT response assessment
in patients with ASCC is not clear. Our study has shown that
MRI performed at 3 and 6 months post-CRT, interpreted using
the TRG system, is helpful in assessing and categorising local
response and in guiding further management.
Traditionally clinical response at 6–8 weeks post-CRT is
considered a predictor of locoregional control [29]. However,
it may take 3–6 months for complete tumour resolution to
occur. In the Anal Cancer Trial (ACT II) the optimum time
to assess complete clinical response was reported as 26 weeks
based on digital rectal examination and abdominopelvic CT;
MRI and positron emission tomography (PET) were not con-
sidered essential [30]. Although clinical assessment is vital, it
is important to be able to assess response non-invasively.
Only a few single-centre, small series have investigated the
role of MRI to image response in ASCC [19]. A study from
the London Royal Marsden investigators of 15 patients sug-
gested that size involution is most evident at 6 months post-
treatment compared with the immediate post-treatment stage
where inflammation is superimposed on treated disease [18].
A study of 35 patients, from the LondonMount Vernon inves-
tigators, showed that early assessment of response by MRI at
6–8 weeks was unhelpful in predicting future clinical outcome
[13]. The present study similarly found a lack of association
between imaging characteristics and DFS. Due to the rarity of
ASCC and lack of bigger series, the optimal timing for therapy
assessment withMRI has not been reported to date [19]. From
the above studies it was anticipated that if MRI assessment is
done within 6–8 weeks post-CRT, not all tumours will have
achieved complete response; we therefore performed MRI
assessment at two time points: 3 months and 6 months post-
completion of CRT.
The accurate and reproducible interpretation of post-CRT
MRI scans in patients with anal SCC is challenging, likely due
to the complexity of anatomy, relative lack of experience due
to rarity of this disease and difficulty in differentiating tumour
signal from post treatment changes. Previous studies have
shown that tumour size change and signal intensity change
post-CRT are not predictive of clinical outcome [13].
Tumour regression grading (TRG) is known to be a better
predictor of outcome after treatment than T stage in rectal
cancers [31]. We therefore used the Mandard TRG system
(Table 1), modified from Dworak et al. [32], to grade tumour
response on MRI and guide further follow-up.
A clinical decision tree for the patient management and
follow-up pathway based on this TRG scoring system is pro-
posed in Fig. 6, but is based on the findings of this study alone
and would need validation with more data from prospective
multicentre trials.
There are some limitations to our study. Firstly, this is a
retrospective study which might lead to recall bias during the
interpretation of imaging. To avoid such bias, clinical and
EUA/biopsy
Salvage surgery6- month post-treatment MRI
Complete responder Indeterminate Partial/Non-
EUA/Biopsy
TRG score 1 or 2 TRG score 3 TRG score 4 or 5
Complete responder Indeterminate Partial/Non-




Completed CRT inguinal boost
3-month post-treatment MRI
- +ve
Fig. 6 Proposed patient follow-
up pathway based on post-
chemoradiotherapy (CRT) mag-
netic resonance imaging (MRI)
tumour regression grading (TRG)
system. SCC squamous cell
carcinoma
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pathological outcomes were unavailable to the reviewers.
There is a selection bias as patients with small anal cancers
that had been removed by excision biopsy were excluded.
Third, despite the relatively large denominator, the number
of events of interest (early local relapse) was small and esti-
mates of performance characteristics and associations with
survival had wide CIs.
The study has several strengths. To our knowledge, this is
the first time that TRG scoring has been reported in the con-
text of anal cancer. We demonstrated that this scoring system
is reproducible in this setting. Second, we comprehensively
characterised imaging features on pre-treatment MRI and
found some (e.g. trans-sphincteric extension) to prognosticate
for DFS, but independence was lost in the multivariate model-
ling, suggesting that these imaging features are in part cap-
tured by T staging. Third, we described a novel ‘tram-track
sign’ on imaging, which, when present, predicted for complete
local response. However, this sign is not applicable to anal
margin tumours and does not prognosticate for survival.
Future research
There are a number of unanswered questions. First, there are
other MRI modalities, such as dynamic post-contrast se-
quences (DCE) and diffusion-weighted imaging (DWI) [23],
and these are currently under investigation as additional as-
sessment for local response. Second, volumetric assessment of
tumour and/or nodal volume as evaluated in other malignan-
cies such as rectal cancer [33], might have a role in tumour
response prediction in ASCC, and is the subject of ongoing
study. Third, the addition of PET to MRI might add further
refinement. A recent meta-analysis [34], albeit with small
numbers of studies, suggests that PET might correctly assess
complete response in over 80 % of cases. Finally, while we
focused on the seven early local relapses in the current analy-
sis, there were an additional four patients with late relapse.
There were no clear predictors for these relapses. This now
needs to be an area of research to better inform surveillance
programmes beyond 12 months. Candidate tissue biomarkers
include lack of p16 expression, which has incomplete concor-
dance with lack of detection of HPV16 [35], and predicts for
radio-resistance [36].
Conclusion
In patients with anal cancers follow-up MRI performed 3 and
6 months post-chemoradiotherapy and scored using the tu-
mour regression grading system allowed reproducible assess-
ment of local tumour response and predicted for early local
relapse. The ‘tram-track’ sign was a predictive indicator of
local response in anal canal tumours. These findings challenge
current clinical guidelines.
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